The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
That’s because there is an inverse relationship between presidential approval ratings and the stock market, according to an analysis conducted by Ned Davis Research. Donald Trump’s approval ...
as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. ENHERTU is a specifically engineered HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback